Understand what your gut health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
A microbiome-made molecule worth measuring
The indole‑3‑propionic acid test measures the concentration of IPA—a small molecule made primarily by certain intestinal bacteria from the amino acid tryptophan—in blood (serum or plasma) or urine. Most labs quantify IPA with high‑specificity methods like liquid chromatography–tandem mass spectrometry (LC‑MS/MS). Because IPA is produced by your microbes rather than by human cells, it serves as a functional readout of microbial metabolism, especially from anaerobes such as Clostridium sporogenes. Results reflect your current ecosystem and inputs (diet, medications, stress), not a fixed trait.
Why a single metabolite connects so many dots
Why it matters: IPA is a potent antioxidant and a signaling molecule. In experimental models, it scavenges harmful free radicals and activates receptors (like PXR) that help tighten intestinal barriers and modulate inflammation. Observational human studies link higher circulating IPA with healthier glucose regulation and lower future risk of type 2 diabetes, and with markers of liver and cardiovascular health, though causation has not been proven. IPA may also cross the blood–brain barrier and has been studied for neuroprotection. In short, this single metabolite connects your microbiome’s behavior to digestion, immunity, and metabolism.
In real life, we feel microbiome changes as symptoms or performance dips: meals that sit heavy, skin that flares, workouts that don’t recover as smoothly. An IPA test translates some of that biologic noise into a readable signal. Low IPA can accompany lower microbial diversity, diminished fiber fermentation, and increased gut permeability—all patterns that may track with bloating, irregularity, fatigue, or metabolic drift. It can also clarify the after‑effects of antibiotics, ultra‑low‑carb or highly restrictive diets, acute infections, or life stress, when microbial metabolism often shifts. Timing matters: IPA is especially informative when you are troubleshooting persistent GI issues, checking in after a big dietary change, or evaluating how your gut is responding to a new routine.
Zooming out, the gut microbiome touches nearly every system—glucose regulation, systemic inflammation, even mood signaling through the gut–brain axis. Watching IPA over time helps you see how fiber intake, fermented foods, or stress management influence microbial function. It is not about chasing a perfect number; it is about pattern recognition that supports prevention and long‑term resilience. If you have heard friends talk about collagen for skin or Ozempic for appetite, think of IPA as the quiet meter for something more foundational: how well your microbes turn everyday foods into protective chemistry.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Translating your concentration
Your report typically shows an IPA concentration (for example, ng/mL or μmol/L in blood, or a urine value often normalized to creatinine) compared with a reference range from a healthy population. In general, “balanced” patterns feature IPA in or near the lab’s reference interval, reflecting active microbial conversion of dietary tryptophan—usually supported by consistent intake of plant fibers and a stable, diverse microbiome. Lower‑than‑expected IPA suggests reduced production, which can occur with recent antibiotics, low fiber availability, suppressed producer species, or higher oxidative and inflammatory stress in the gut environment.
When IPA sits comfortably in range, it often aligns with efficient digestion, a more intact gut barrier, and a quieter inflammatory tone. Those conditions favor the production of short‑chain fatty acids (SCFAs) by other microbes as well, which together support glucose handling and lipid metabolism. “Optimal” varies person to person, shaped by genetics, geography, and habitual diet, so a single snapshot should be read in context rather than treated as a verdict.
When IPA is low, the signal is not a diagnosis—it is a prompt to consider mechanisms. Are fiber and polyphenols reaching the colon where producer microbes live? Has there been recent antimicrobial or acid‑suppressing medication use? Are symptoms or other labs hinting at mucosal inflammation or increased permeability? In some settings, very low IPA has been observed alongside insulin resistance, fatty liver risk, or active gut inflammation, but associations do not prove causation and clinical evaluation is essential if symptoms persist. Markedly high values are uncommon and may reflect assay differences, sample timing, or unusual diet patterns; your clinician will interpret these in context.
What an IPA test adds and doesn't
The bottom line: the indole‑3‑propionic acid test gives you a clear, quantifiable window into how your gut microbes are performing today. Read alongside your history, symptoms, and complementary labs, it helps convert everyday choices—like the plants on your plate or the recovery time you protect—into measurable shifts in gut‑driven chemistry that supports long‑term health.
Frequently Asked Questions
References
- Sehgal R, de Mello VD, Männistö V, Lindström J, Tuomilehto J, Pihlajamäki J, Uusitupa M (2022). Indolepropionic acid, a gut bacteria-produced tryptophan metabolite and the risk of type 2 diabetes and non-alcoholic fatty liver disease. *Nutrients*, *14*(21), 4695. https://doi.org/10.3390/nu14214695
- Mann ER, Lam YK, Uhlig HH (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. *Nature Reviews Immunology*, *24*(8), 577-595. https://doi.org/10.1038/s41577-024-01014-8
- Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong GK (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. *Frontiers in Microbiology*, *7*, 459. https://doi.org/10.3389/fmicb.2016.00459
- Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. *New England Journal of Medicine*, *375*(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
- Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. *Clinical Gastroenterology and Hepatology*, *17*(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017
